Objective ESPRITE (Study 508; NCT03836924) evaluated the real‐world safety, tolerability, and efficacy of adjunctive perampanel in patients aged ≥12 years with focal‐onset seizures (FOS), with or without focal to bilateral tonic–clonic seizures (FBTCS ...
Sangeeta Ravat +6 more
doaj +1 more source
Objective The Prince of Wales Hospital (PWH) Real‐world Analysis of People with Drug‐Resistant Epilepsy (DRE) on PERampanel (WRAPPER) study assessed effectiveness and tolerability of adjunctive perampanel in people with DRE attending PWH.
Charlie C. H. Chan, Ho Wan Leung
doaj +1 more source
Neuroimmunomodulation of AMPA Receptors Through Combination of Medium-Chain Triglycerides and Perampanel to Treat Status Epilepticus in Anti-NMDA Receptor Encephalitis. [PDF]
Stadler LM +7 more
europepmc +1 more source
Repurposing CNS drugs Zonisamide and Perampanel conjugated with silver nanoparticles as an anti-amoebic agent in combating Granulomatous Amebic Encephalitis (GAE) and Primary Amebic Meningoencephalitis (PAM) infection caused by <i>Acanthamoeba castellanii</i> and <i>Naegleria Fowleri</i>. [PDF]
Apparasamy D +8 more
europepmc +1 more source
SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol. [PDF]
Eschen JT +10 more
europepmc +1 more source
Identification of De Novo <i>ZBTB18</i> Variant in a Patient With Global Developmental Delay, Seizures, and Juvenile Facies. [PDF]
Wu Y, Li B, Liu L, Wang Y, Li D.
europepmc +1 more source
Pharmacokinetics of Perampanel in Danish Paediatric Patients With Epilepsy Based on Therapeutic Drug Monitoring. [PDF]
Angelucci S +5 more
europepmc +1 more source

